Combination antibiotic treatment of serious methicillin-resistant Staphylococcus aureus infections

Joshua Davis, Sebastian van Hal, Steven Tong

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Outcomes from methicillin-resistant Staphylococcus aureus (MRSA) infections are relatively poor, at least in part due to the limitations of vancomycin (the current standard treatment for MRSA). Combination antibiotic treatment for MRSA infections is an attractive alternative as it could address most of vancomycin's shortcomings, including poor tissue penetration, slow bacterial killing, and emerging resistance in some strains of MRSA. However, the theoretical promise of combination therapy for MRSA infections has not been borne out in most in vitro and animal studies. Multiple combinations have been tested and have been either antagonistic, indifferent, or have had conflicting findings in various studies. This includes combinations of two primarily active agents (such as vancomycin plus daptomycin or linezolid), or the addition of gentamicin or rifampin to either vancomycin or daptomycin. However, hope on this front has come from an unexpected quarter. Although MRSA is by definition inherently resistant to nearly all β-lactam antibiotics, this class of drugs has consistently shown evidence of synergy with either daptomycin or vancomycin in over 25 separate in vitro studies, and a limited number of animal and human observational studies. However, there are currently insufficient data to recommend β-lactam combination therapy in routine clinical use. Results of current and planned randomized controlled trials of this strategy are awaited.
Original languageEnglish
Pages (from-to)3-16
Number of pages14
JournalSeminars in Respiratory and Critical Care Medicine
Volume36
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Vancomycin
Daptomycin
Anti-Bacterial Agents
Infection
Lactams
Linezolid
Rifampin
Gentamicins
Observational Studies
Randomized Controlled Trials
Therapeutics
Pharmaceutical Preparations

Cite this

@article{300e9bf88f694e7793dc58a529e7bfc7,
title = "Combination antibiotic treatment of serious methicillin-resistant Staphylococcus aureus infections",
abstract = "Outcomes from methicillin-resistant Staphylococcus aureus (MRSA) infections are relatively poor, at least in part due to the limitations of vancomycin (the current standard treatment for MRSA). Combination antibiotic treatment for MRSA infections is an attractive alternative as it could address most of vancomycin's shortcomings, including poor tissue penetration, slow bacterial killing, and emerging resistance in some strains of MRSA. However, the theoretical promise of combination therapy for MRSA infections has not been borne out in most in vitro and animal studies. Multiple combinations have been tested and have been either antagonistic, indifferent, or have had conflicting findings in various studies. This includes combinations of two primarily active agents (such as vancomycin plus daptomycin or linezolid), or the addition of gentamicin or rifampin to either vancomycin or daptomycin. However, hope on this front has come from an unexpected quarter. Although MRSA is by definition inherently resistant to nearly all β-lactam antibiotics, this class of drugs has consistently shown evidence of synergy with either daptomycin or vancomycin in over 25 separate in vitro studies, and a limited number of animal and human observational studies. However, there are currently insufficient data to recommend β-lactam combination therapy in routine clinical use. Results of current and planned randomized controlled trials of this strategy are awaited.",
keywords = "antibiotic agent, beta lactam antibiotic, cefazolin, ceftaroline, ceftobiprole, ceftriaxone, clindamycin, cloxacillin, cotrimoxazole, dalfopristin plus quinupristin, daptomycin, fosfomycin, gentamicin, imipenem, linezolid, meropenem, nafcillin, oritavancin, oxacillin, rifampicin, telavancin, tetracycline derivative, tigecycline, vancomycin, animal experiment, antibiotic therapy, Article, human, human experiment, in vitro study, methicillin resistant Staphylococcus aureus infection, nonhuman, phase 2 clinical trial (topic), priority journal, randomized controlled trial (topic), systematic review (topic)",
author = "Joshua Davis and {van Hal}, Sebastian and Steven Tong",
year = "2015",
doi = "10.1055/s-0034-1396906",
language = "English",
volume = "36",
pages = "3--16",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "1",

}

Combination antibiotic treatment of serious methicillin-resistant Staphylococcus aureus infections. / Davis, Joshua; van Hal, Sebastian; Tong, Steven.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 36, No. 1, 2015, p. 3-16.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Combination antibiotic treatment of serious methicillin-resistant Staphylococcus aureus infections

AU - Davis, Joshua

AU - van Hal, Sebastian

AU - Tong, Steven

PY - 2015

Y1 - 2015

N2 - Outcomes from methicillin-resistant Staphylococcus aureus (MRSA) infections are relatively poor, at least in part due to the limitations of vancomycin (the current standard treatment for MRSA). Combination antibiotic treatment for MRSA infections is an attractive alternative as it could address most of vancomycin's shortcomings, including poor tissue penetration, slow bacterial killing, and emerging resistance in some strains of MRSA. However, the theoretical promise of combination therapy for MRSA infections has not been borne out in most in vitro and animal studies. Multiple combinations have been tested and have been either antagonistic, indifferent, or have had conflicting findings in various studies. This includes combinations of two primarily active agents (such as vancomycin plus daptomycin or linezolid), or the addition of gentamicin or rifampin to either vancomycin or daptomycin. However, hope on this front has come from an unexpected quarter. Although MRSA is by definition inherently resistant to nearly all β-lactam antibiotics, this class of drugs has consistently shown evidence of synergy with either daptomycin or vancomycin in over 25 separate in vitro studies, and a limited number of animal and human observational studies. However, there are currently insufficient data to recommend β-lactam combination therapy in routine clinical use. Results of current and planned randomized controlled trials of this strategy are awaited.

AB - Outcomes from methicillin-resistant Staphylococcus aureus (MRSA) infections are relatively poor, at least in part due to the limitations of vancomycin (the current standard treatment for MRSA). Combination antibiotic treatment for MRSA infections is an attractive alternative as it could address most of vancomycin's shortcomings, including poor tissue penetration, slow bacterial killing, and emerging resistance in some strains of MRSA. However, the theoretical promise of combination therapy for MRSA infections has not been borne out in most in vitro and animal studies. Multiple combinations have been tested and have been either antagonistic, indifferent, or have had conflicting findings in various studies. This includes combinations of two primarily active agents (such as vancomycin plus daptomycin or linezolid), or the addition of gentamicin or rifampin to either vancomycin or daptomycin. However, hope on this front has come from an unexpected quarter. Although MRSA is by definition inherently resistant to nearly all β-lactam antibiotics, this class of drugs has consistently shown evidence of synergy with either daptomycin or vancomycin in over 25 separate in vitro studies, and a limited number of animal and human observational studies. However, there are currently insufficient data to recommend β-lactam combination therapy in routine clinical use. Results of current and planned randomized controlled trials of this strategy are awaited.

KW - antibiotic agent

KW - beta lactam antibiotic

KW - cefazolin

KW - ceftaroline

KW - ceftobiprole

KW - ceftriaxone

KW - clindamycin

KW - cloxacillin

KW - cotrimoxazole

KW - dalfopristin plus quinupristin

KW - daptomycin

KW - fosfomycin

KW - gentamicin

KW - imipenem

KW - linezolid

KW - meropenem

KW - nafcillin

KW - oritavancin

KW - oxacillin

KW - rifampicin

KW - telavancin

KW - tetracycline derivative

KW - tigecycline

KW - vancomycin

KW - animal experiment

KW - antibiotic therapy

KW - Article

KW - human

KW - human experiment

KW - in vitro study

KW - methicillin resistant Staphylococcus aureus infection

KW - nonhuman

KW - phase 2 clinical trial (topic)

KW - priority journal

KW - randomized controlled trial (topic)

KW - systematic review (topic)

UR - http://www.scopus.com/inward/record.url?scp=84964284880&partnerID=8YFLogxK

U2 - 10.1055/s-0034-1396906

DO - 10.1055/s-0034-1396906

M3 - Article

VL - 36

SP - 3

EP - 16

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 1

ER -